-
acquired by
Mereo BioPharma and
delisted from the Nasdaq.
Oncomed was
founded in 2004. In 2007,
Oncomed consolidated its
operations located in
Mountain View...
- and is
currently undergoing phase 2 trials.
Demcizumab was
developed by
OncoMed Pharmaceuticals in
collaboration with Celgene.
Demcizumab blocks Delta-like...
-
corporation owns 50% of two subsidiaries,
Oncotec GmbH in
Dessau Germany and
oncomed manufacturing a.s. in the
Czech Republic city of Brno, for the production...
-
antibody designed for the
treatment of cancer. This drug was
developed by
OncoMed Pharmaceuticals.
World Health Organization (2016). "International Nonproprietary...
-
treatment of cancer. It
blocks the NOTCH1 receptor. This drug was
developed by
OncoMed Pharmaceuticals.
Statement On A
Nonproprietary Name
Adopted By The USAN...
- Magazine's
number 2
ranked drug
company of 2013. In 2014,
Celgene and
OncoMed Pharmaceuticals joined a
cancer stem cell
therapeutic development agreement...
- by SAP AG. Its
Redwood City
office was
later occupied by
ApniCure and
OncoMed Pharmaceuticals Inc. The
first issue of
NeXTWORLD magazine was printed...
-
treatment of cancer. This drug was
developed by
OncoMed Pharmaceuticals Inc. in
partnership with Bayer.
OncoMed was
awarded a
patent in 2016,
which is set...
- pipeline, and in 2010,
decided to a
focus on
oncology and immunology.
OncoMed Pharmaceuticals and Five
Prime Therapeutics are
among Compugen's competitors...
-
Abbott Vascular Paul Hastings,
president and
chief executive officer,
OncoMed Pharmaceuticals;
Terry Hermiston, Ph.D., vice president, U.S. Biologics...
